These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 32243959)
1. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959 [TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002 [TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841 [TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
5. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544 [TBL] [Abstract][Full Text] [Related]
6. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Faillaci F; Marzi L; Critelli R; Milosa F; Schepis F; Turola E; Andreani S; Vandelli G; Bernabucci V; Lei B; D'Ambrosio F; Bristot L; Cavalletto L; Chemello L; Sighinolfi P; Manni P; Maiorana A; Caporali C; Bianchini M; Marsico M; Turco L; de Maria N; Del Buono M; Todesca P; di Lena L; Romagnoli D; Magistri P; di Benedetto F; Bruno S; Taliani G; Giannelli G; Martinez-Chantar ML; Villa E Hepatology; 2018 Sep; 68(3):1010-1024. PubMed ID: 29604220 [TBL] [Abstract][Full Text] [Related]
7. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045 [TBL] [Abstract][Full Text] [Related]
8. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M; Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220 [TBL] [Abstract][Full Text] [Related]
9. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M; Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361 [TBL] [Abstract][Full Text] [Related]
10. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003 [TBL] [Abstract][Full Text] [Related]
11. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729 [TBL] [Abstract][Full Text] [Related]
12. Risk of Antwi SO; Van Houten HK; Sangaralingham LR; Patel T Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519 [TBL] [Abstract][Full Text] [Related]
13. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV). Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565 [TBL] [Abstract][Full Text] [Related]
14. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
15. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183 [TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
17. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506 [TBL] [Abstract][Full Text] [Related]
18. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405 [TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694 [TBL] [Abstract][Full Text] [Related]
20. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL; Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]